Cell: Chinese scientists develop a SARS-CoV-2 inactivated vaccine, BBIBP-CorV, animal experiments show effective protective effects

, June 9, 2020 /

BIOON/BIOON/-- The 2019 coronavirus pandemic caused by Severe Acute Respiratory Syndrome (SARS-CoV-2) threatens global public healthIn order to prevent and control COVID-19, there is an urgent need to develop a vaccineRevealing the data released by the WHO on June 2nd, 10 vaccines have entered clinical trials worldwide, one of which is in Phase 3 clinical trial s/7, researchers from Beijing Institute of Biological Products Co., Ltd., China Center for Disease Control and Prevention, Beijing Concord Medical College, the State Food and Drug Administration and Tsinghua University published a new study in cell published in cell magazine, presenting a new inactivated candidate vaccine, BBIBP-CorV, which showed that the vaccine can induce a strong protective immune response to SARS-CoV-2Photo Source: Cell
Highlights of the study include:developed an inactivated SARS-CoV-2 candidate vaccine, BBIBP-CorV,, the introduction of high concentrations of neutral antibodies in animal models,two injections of the vaccine (2 ug/times) to protect rhesus monkeys from SARS-CoV-2 infection, and-CoV-2 can be produced efficientlyin the study, researchers reported on the experimental production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV)In animal trials, researchers found that the vaccine induced high levels of neutralizing antibody titer in mice, rats, guinea pigs, rabbits and non-human primates (crab-eating and rhesus monkeys) to provide protection against SARS-CoV-2researchers found that two 2 ug/times of the BBIBP-CorV vaccine against rhesus provided effective protection against the sars-CoV-2 trachea challenge in rhesus monkeys, withsoftwarepark saying no antibody-dependent infections were detectedIn addition, the researchers found that BBIBP-CorV showed efficient productivity and good genetic stability in vaccine production during the production process These results support further evaluation of BBIBP-CorV in the of clinical trials (BioValleyBioon.com) References: Hui Wang et al.
Development of an inactivated vaccine candidate, BBIBP-CorV, with ding dweeddd us against SARS-CoV-2.
Cell 2020 DOI: https://doi.org/10.1016/j.cell.2020.06.008